cytarabine and everolimus

cytarabine has been researched along with everolimus in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (16.67)	29.6817
2010's	4 (66.67)	24.3611
2020's	1 (16.67)	2.80

Authors

Authors	Studies
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Bagg, A; Carroll, M; Scialla, TJ; Simpson, SE; Xu, Q	1
Béné, MC; Bories, P; Bouscary, D; Cahn, JY; Chapuis, N; Chevallier, P; Delepine, R; Demur, C; Dreyfus, F; Ifrah, N; Lacombe, C; Lamy, T; Leguay, T; Mayeux, P; Merlat, A; Park, S; Prebet, T; Recher, C; Saint Marcoux, F; Tamburini, J; Vey, N; Witz, F	1
Catalano, J; Cummings, N; Hills, R; McManus, J; Sadawarte, S; Tan, P; Tiong, IS; Wei, A	1
Böll, B; Borchmann, P; Borchmann, S; Bröckelmann, PJ; Eichenauer, DA; Engert, A; Fuchs, M; Gillessen, S; Haverkamp, H; Heger, JM; Hüttmann, A; Kobe, C; Müller, H; Plütschow, A; Sasse, S; Schmitz, C; Topp, MS; Viardot, A; von Tresckow, B; Vucinic, V	1

Reviews

1 review(s) available for cytarabine and everolimus

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Trials

3 trial(s) available for cytarabine and everolimus

Article	Year
A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse. Leukemia, 2013, Volume: 27, Issue:7 Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Everolimus; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome; Young Adult	2013
Phase Ib study of the mTOR inhibitor everolimus with low dose cytarabine in elderly acute myeloid leukemia. Leukemia & lymphoma, 2018, Volume: 59, Issue:2 Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Everolimus; Humans; Leukemia, Myeloid, Acute; Survival Analysis; TOR Serine-Threonine Kinases; Treatment Outcome	2018
Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group ( British journal of haematology, 2022, Volume: 196, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Drug Resistance, Neoplasm; Everolimus; Female; Germany; Hodgkin Disease; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Recurrence; Remission Induction; Retreatment; Young Adult	2022

Other Studies

2 other study(ies) available for cytarabine and everolimus

Article	Year
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood, 2003, Aug-01, Volume: 102, Issue:3 Topics: Acute Disease; Animals; Cell Survival; Cytarabine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; Everolimus; Humans; Leukemia, Myeloid; Mice; Mice, SCID; Neoplasms, Experimental; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; Transplantation, Heterologous	2003

Article

Year

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.

Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013

Survival of acute myeloid leukemia cells requires PI3 kinase activation.

Blood, 2003, Aug-01, Volume: 102, Issue:3

Topics: Acute Disease; Animals; Cell Survival; Cytarabine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; Everolimus; Humans; Leukemia, Myeloid; Mice; Mice, SCID; Neoplasms, Experimental; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; Transplantation, Heterologous

2003